Investor Overview Press Releases February 27, 2024 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update January 16, 2024 Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review January 10, 2024 Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis View all » Events Nov 13, 20238:00 AM EST Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Sep 26, 202310:30 AM EDT Aclaris Therapeutics at 2023 Cantor Global Healthcare Conference Jun 14, 20234:40 PM PDT Aclaris Therapeutics at 44th Annual Goldman Sachs Healthcare Conference View all » Feature Presentation Aclaris Therapeutics Company Overview – November 2023
February 27, 2024 Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
January 10, 2024 Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Nov 13, 20238:00 AM EST Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results